Y
ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Cardiology · BMJ · 2026-11-12

In 12,434 adults with type 2 diabetes, targeting systolic BP below 120 instead of 140 mm Hg did not reduce dementia or mild cognitive impairment over about 4 years (HR 0.96). An MRI substudy showed slower growth of white matter lesions.

Secondary analysisn = 12,434
Wang et al. Effect of intensive blood pressure control on cognitive outcomes and brain structures in adults with type 2 diabetes: prespecified analysis of secondary outcomes of BPROAD randomised controlled trial
Cardiology · Lancet · 2026-09-30

In 2749 adults with type 2 diabetes and high cardiovascular risk, oral orforglipron was non-inferior to insulin glargine for MACE-4 over 2 years (4.2% vs 5.0%; HR 0.84, 95% CI 0.59-1.20). GI adverse events were more common (62% vs 14%).

RCTn = 2,749
Klein et al. Cardiovascular safety of orforglipron versus insulin glargine in adults with type 2 diabetes at increased cardiovascular risk (ACHIEVE-4): a phase 3, event-driven, randomised, open-label, non-inferiority, active comparator trial
Cardiology · Circulation · 2026-08-18

In a prespecified secondary analysis of SELECT (17,604 adults with CVD and overweight/obesity, no diabetes), semaglutide cut hsCRP by 37.8% at 104 weeks, including without weight loss, and cut MACE vs placebo across hsCRP subgroups. Higher baseline hsCRP predicted MACE.

Secondary analysisn = 17,604
Plutzky et al. Effect of Semaglutide on the Inflammatory Biomarker High-Sensitivity CRP in Patients With Established Cardiovascular Disease and Overweight or Obesity in SELECT: A Prespecified Secondary Analysis

Sign in to react

Enter your email and we send a one-time link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.